Inflammatory cytokines and markers

Inflammatory cytokines and markers represent a broad class of signaling proteins and biochemical indicators that mediate and reflect the body's inflammatory response to stimuli such as infection, tissue injury, or malignancy [1, 7]. Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), act as primary messengers that activate immune cells and orchestrate systemic effects like fever and the acute-phase response [9, 14]. These molecules are critical for host defense but can drive chronic pathology, including autoimmune diseases and cytokine storms, when their production is dysregulated [6, 7]. Inflammatory markers, such as C-reactive protein (CRP) and procalcitonin, are clinical tools used to assess the severity of inflammation and monitor therapeutic efficacy [1, 15]. In drug development, specific cytokines and their receptors are major therapeutic targets for biologics and small-molecule inhibitors designed to treat conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease [4, 10]. Therapeutic strategies include the use of monoclonal antibodies to neutralize soluble cytokines, receptor antagonists to block signaling, and small molecules like JAK inhibitors to suppress downstream pathways [6, 8]. While highly effective, targeting these mediators carries risks of immunosuppression and increased susceptibility to opportunistic infections [6, 15]. Monitoring these markers is essential in clinical trials to evaluate drug pharmacodynamics and patient response [13, 15].

Other names

Pro-inflammatory mediatorsInflammatory biomarkersAcute phase reactantsCytokine profileInflammatory mediators

Neutralization of soluble cytokines, competitive inhibition of cytokine receptors, inhibition of intracellular signaling pathways (e.g., JAK/STAT), and suppression of cytokine gene expression.